Joenja®

Search documents
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
Globenewswire· 2025-10-01 05:00
If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDSPDUFA target action date of January 31, 2026 Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administr ...
Pharming N.V.(PHAR) - 2025 Q2 - Earnings Call Presentation
2025-07-31 11:30
Pharming Group N.V. Second quarter and first half 2025 financial results and business update July 31, 2025 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM Fabrice Chouraqui Chief Executive Officer Stephen Toor Chief Commercial Officer Anurag Relan, MD Chief Medical Officer SPEAKERS Forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known ...